Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.3900 (-0.55%) ($5.2800 - $5.4600) on Fri. Sep. 4, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.85% (three month average) | RSI | 58 | Latest Price | $5.3900(-0.55%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1% a day on average for past five trading days. | Weekly Trend | ADMS advances 4.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) BND(33%) BNDX(33%) VIXM(29%) VCIT(23%) TLT(21%) | Factors Impacting ADMS price | ADMS will decline at least -3.925% in a week (0% probabilities). GDX(-21%) XLU(-20%) URA(-20%) GDXJ(-19%) TBT(-17%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.925% (StdDev 7.85%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.28(2.08%) | 10 Day Moving Average | $5.09(5.89%) | 20 Day Moving Average | $4.95(8.89%) | To recent high | -0.6% | To recent low | 6.7% | Market Cap | $152m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |